Is there an association between 5‑fluorouracil (5‑FU) and mitomycin C and cutaneous infection, cellulitis, or skin necrosis?

Association Between 5-FU/Mitomycin C and Cutaneous Complications

Yes, there is a well-established association between mitomycin C and cutaneous complications including cellulitis and skin necrosis, particularly with extravasation, while 5-FU is primarily associated with other dermatological toxicities rather than cellulitis or infection.

Mitomycin C: High Risk for Cellulitis and Skin Necrosis

Direct FDA-Documented Risks

Mitomycin C carries significant cutaneous toxicity risks that are explicitly documented in its FDA labeling:

• Cellulitis at the injection site occurs in approximately 4% of patients and can be occasionally severe 1
• Skin necrosis and tissue sloughing are the most important dermatological problems, occurring when the drug extravasates during injection 1
• Extravasation can occur with or without warning signs (stinging, burning) and even when blood return appears adequate on aspiration 1

Critical Timing and Presentation

The cutaneous manifestations of mitomycin C can be particularly insidious:

• Delayed erythema and ulceration can occur weeks to months after administration, even at sites distant from the injection location and without obvious extravasation during administration 1
• Skin grafting has been required in some cases due to the severity of tissue damage 1
• Elderly patients are more susceptible to injection site reactions compared to younger patients 1

Clinical Evidence of Severity

Case reports confirm the serious nature of these complications:

• Mitomycin C extravasation can cause extensive soft-tissue injury requiring hospital admission and surgical intervention, including removal of implantable venous access devices 2
• The spectrum ranges from local skin irritation and inflammation to erythema, ulcerations, and frank necrosis 2

5-Fluorouracil: Different Toxicity Profile

Primary Dermatological Manifestations

5-FU has a distinct cutaneous toxicity pattern that does not typically include cellulitis or infection:

• Common reactions include burning, crusting, allergic contact dermatitis, pruritus, scarring, rash, soreness, and ulceration 3
• Palmar-plantar erythrodysesthesia syndrome (PPES) occurs in 6-34% of patients with 5-FU, characterized by redness, discomfort, swelling, and tingling 4
• Hyperpigmentation, maculo-papular eruption, and PPES are the typical manifestations, which reverse promptly with drug discontinuation 5

Rare Hypersensitivity Reactions

While not infectious in nature, 5-FU can cause localized inflammatory reactions:

• Localized erythema multiforme-like reactions have been reported, particularly when combined with mitomycin C 6
• Cutaneous recall reactions can occur on previously treated or sun-damaged skin when 5-FU is given systemically 7

Combined Therapy: Additive Toxicity Risk

Severe Skin Toxicity with Combination Regimens

When 5-FU and mitomycin C are used together, particularly with radiation:

• Grade 3 skin toxicity occurred in 6 patients and grade 2 in 7 patients in a series of 17 patients receiving chemoradiation 8
• One patient developed grade 4 skin toxicity in the vulvar-perineal area 8
• Skin toxicity necessitated treatment interruption in 9 patients at a median dose of 32.4 Gy 8
• Severe enterocolitis was a direct cause of death in 2 patients, highlighting the systemic toxicity potential 8

Clinical Management Implications

Prevention and Monitoring

For mitomycin C administration:

• Ensure proper IV access and monitor closely during infusion to prevent extravasation 1
• Be vigilant for delayed reactions occurring weeks to months post-administration 1
• Exercise heightened caution in elderly patients 1

For suspected infection versus drug toxicity:

• Obtain bacterial/viral/fungal cultures if infection is suspected in patients with grade ≥3 dermatological toxicity 4
• Distinguish between true cellulitis (infectious) and drug-induced inflammation (sterile) 1

Treatment Approach

For mitomycin C extravasation or severe local reactions:

• Stop the infusion immediately and remove the catheter 2
• Surgical debridement may be necessary for established necrosis 2
• Skin grafting may be required in severe cases 1

For inflammatory dermatological toxicity:

• Topical low/moderate strength steroids for grade 2 reactions 4
• Systemic corticosteroids (prednisone 0.5-1 mg/kg for 7 days) for grade ≥3 reactions 4
• Oral antibiotics for 6 weeks (doxycycline 100 mg b.i.d. or alternatives) if superinfection is suspected 4

Key Clinical Pitfall

The most critical pitfall is assuming that all skin reactions represent infection requiring antibiotics alone. Mitomycin C causes sterile inflammation and necrosis that may mimic cellulitis but requires different management including potential surgical intervention 1, 2. True superinfection should be confirmed with cultures before attributing symptoms solely to bacterial cellulitis 4.